This finding was corroborated by previous findings indicating that FGFR1 amplification was significantly associated with overexpression of FGFR1, drove anchorage-independent cell proliferation, and enhanced resistance to endocrine therapy [22,23], as well as mediated resistance to cyclin-dependent kinase 4/6 inhibitors in breast cancer [24]. The gene discussed is CDK4; the disease is breast cancer.